Benzenesulfonamide Influenza Inhibitor SAR Data

A 2026 study from figshare details the structure-activity relationship of over 80 sulfonyl-containing analogs designed as influenza A virus hemagglutinin inhibitors. The dataset includes potency measurements (EC50) for compounds like SHJ-027 and (S)-63, with the lead compound showing over 10-fold enhanced potency against an oseltamivir-resistant H1N1 strain. In vivo efficacy data from a lethal mouse model is also provided, showing compounds achieving 20–30% survival.

Use Cases

• Analyze EC50 potency values across the >80 sulfonyl analogs to identify key structural features for influenza HA inhibition.
• Compare in vivo survival rates for lead compounds like (S)-63 and 27 against the parent scaffold F0045(S) to validate efficacy improvements.
• Model the structure-activity relationship (SAR) using chemical structure data to predict compound potency against oseltamivir-resistant strains.

Strengths

• Includes potency data (EC50) for over 80 synthesized chemical analogs.
• Provides in vivo efficacy results from a lethal influenza mouse model, showing survival rates of 20–30% for lead compounds.
• Data is recent, published on the figshare platform in March 2026.

Limitations

• The dataset is very small at 10.4 KB, indicating limited scope and likely a summary table rather than raw experimental data.
• Specific column names and row counts are not provided, limiting immediate understanding of the data structure.
• Data is focused on a specific chemical series (benzenesulfonamides), which may limit generalizability to other antiviral scaffolds.

Provenance

Source

figshare, authored by Huijuan Song.

Collection Method

Data generated from a systematic structure-activity relationship (SAR) study involving chemical synthesis and biological assays.

Time Range

null

Freshness

Last updated 2026-03-25.

Geography

null